Skip to main content
. Author manuscript; available in PMC: 2022 Jul 1.
Published in final edited form as: Cancer Discov. 2021 Nov 9;12(1):62–73. doi: 10.1158/2159-8290.CD-21-1033

Figure 2: Predictors of mortality during acute SARS-CoV-2 infection in patients with lymphoma.

Figure 2:

a) Multivariate analysis of clinical risk factors predicting mortality attributable to COVID-19 infection in patients with lymphoma. Statistically significant risk factors highlighted in red. b) Left, two-dimensional Uniform Manifold Approximation and Projection (UMAP) of laboratory data for 36 patients with lymphoma in whom at least 10% of all laboratory analyses were conducted. Missing data is imputed. Right, description of three patient clusters generated based on Earth Mover’s Distance (EMD) of each patient relative to each other in UMAP space. c) Laboratory markers in patients who were alive or dead following acute COVID-19 infection. d) Kaplan-Meier curve displaying probability of survival within 60 days of acute COVID-19 infection in patients with decreased CD8+ or CD4+ T-cell counts. **p<0.01. ***p<0.001. ****p<0.0001.